Search company, investor...

Founded Year

1987

Stage

Acq - P2P | Acquired

Valuation

$0000 

About MedImmune

MedImmune develops and markets products that address medical needs in areas such as infectious disease, immune regulation and cancer.

Headquarters Location

One MedImmune Way

Gaithersburg, Maryland, 20878,

United States

301-398-0000

Loading...

Loading...

MedImmune Patents

MedImmune has filed 773 patents.

The 3 most popular patent topics include:

  • monoclonal antibodies
  • clusters of differentiation
  • immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/27/2020

2/20/2024

Dosage forms, Drug delivery devices, Glucocorticoids, Monoclonal antibodies, Immunology

Grant

Application Date

10/27/2020

Grant Date

2/20/2024

Title

Related Topics

Dosage forms, Drug delivery devices, Glucocorticoids, Monoclonal antibodies, Immunology

Status

Grant

Latest MedImmune News

Brain Cancer Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Medicenna, Servier, Genentech, Merck, Daiichi Sankyo, Bayer, MedImmune, Immunomic

Jan 10, 2024

Delveinsight Business Research LLP As per DelveInsight, the Brain Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Brain Cancer and the launch of new therapies in the market. DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Brain Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan). The report covers emerging Brain Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Brain Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. Brain Cancer: An Overview A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases that have in common the abnormal development of mass lesions in the brain, spinal cord, or its coverings. A brain tumor can be classified into two main groups, i.e., primary and metastatic. A primary brain tumor is often described as “low grade” or “high grade.” A low-grade tumor generally grows slowly, but it can turn into a high-grade tumor, whereas a high-grade tumor is more likely to grow faster. Secondary brain tumors, also called brain metastases, are much more common than primary tumors in adults. Primary brain tumors originate in the brain itself or tissues close to it, such as in the brain-covering membranes (meninges), cranial nerves, pituitary gland, or pineal gland. Brain cancer cells may travel short distances within the brain, but generally do not spread beyond the brain. Primary tumors are categorized as glial (composed of glial cells) or non-glial (developed on or in the brain’s structures, including nerves, blood vessels, and glands). They can also be divided into malignant or benign tumors. The most common types of primary tumors in adults are meningiomas and astrocytomas, such as glioblastoma multiforme (GBM). In children, the most common types of brain tumors include medulloblastomas, low-grade astrocytomas (pilocytic), ependymomas, craniopharyngiomas, and brainstem gliomas. Brain Cancer Market Key Facts The Brain Tumor market size in the seven major markets was estimated to be USD 2,089.4 Million in 2020. The United States accounts for the largest market size of USD 986.0 Million in 2020 compared to EU5 (Italy, Germany, France, Spain, and the UK) and Japan, respectively. Among the EU5 countries, Italy had the highest market size with USD 214.4 Million in 2020, while the United Kingdom had the lowest market size with USD 129.8 Million in 2020. The Japan Brain Tumors market accounted for USD 256.7 Million in 2020. The total incident population of Primary Brain Tumors in the 7 major markets was estimated to be 60,100+ in 2020. In the case of Primary Brain Tumors patients in the United States, the incident cases were 23,000+ in 2020. In the United States, the incidence of Brain Tumors was 13,500+ in males and 9,500+ in females, in 2020. In the EU5 countries, the incident population of Primary Brain Tumors was maximum in Italy with 7,300+ cases, followed by Germany with 7,100+ cases in 2020. While the United Kingdom accounted for the lowest incident population of the indication with 4,400+ cases in 2020. Japan had 8,100+ incident cases of Primary Brain Tumors in 2020. The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Brain Cancer pipeline therapies. It also thoroughly assesses the Brain Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics. The report gives complete details of the market trend for each marketed Brain Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market. Brain Cancer Epidemiology Assessment The epidemiology section provides insights into the historical, current, and forecasted Brain Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Brain Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. The Report Covers the Brain Cancer Epidemiology, Segmented as – Total Incidence of Primary Brain Tumors Grade-specific Incidence of Brain Tumors Type-specific Incidence of Brain Tumors Gender-specific Incidence of Brain Tumors Age-specific Incidence of Brain Tumors Brain Cancer Drugs Uptake and Pipeline Development Activities The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Brain Cancer market or expected to be launched during the study period. The analysis covers the Brain Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Brain Cancer drugs based on their sale and market share. The report also covers the Brain Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Brain Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Learn How the Brain Cancer Market Will Evolve and Grow by 2032 @ Brain Cancer Therapeutics Analysis Treatment options for brain cancers include surgery, radiation therapy, chemotherapy, and targeted therapy. The treatment options and recommendations depend on several factors like the size, type, and grade of the tumor, whether the tumor is putting pressure on vital parts of the brain if the tumor has spread to other parts of the CNS or the body, the possible side effects and finally, the treatment preferences and overall health of the patient. GBM is not curable and approved treatment options are limited. The tumor is characterized by a high recurrence rate and poor patient prognosis. For these reasons, there is an urgent need for new and efficient treatments such as immunotherapy, gene therapy, and more specific targeted therapies, which will extend the progression-free OS of the patients. Several key players such as Eisai, Medicenna Therapeutics, Immunomic Therapeutics, Bayer, and others are undergoing different clinical trials for brain tumors such as GBM, and others. Brain Cancer Companies Actively Working in the Therapeutics Market Include Some of the key companies in the Brain Cancer market include Orbus Therapeutics, Kazia Therapeutics, Bayer, MedImmune, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Servier, Genentech, Merck, Arbor Pharmaceuticals, Daiichi Sankyo, and others. Emerging and Marketed Brain Cancer Therapies Covered in the Report Include: Some of the major Brain Cancer Therapies in various states of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), Eflornithine (Orbus Therapeutics) and Regorafenib (Bayer), Durvalumab (MEDI4736; MedImmune), Tasadenoturev (DNX-2401; DNAtrix), ONC201 (Oncoceutics), Selinexor (KPT-330; Karyopharm Therapeutics), VBI-1901 (VBI Vaccines), Paxalisib (GDC-0084; Kazia Therapeutics), AV-GBM-1 (Aivita Biomedical), MDNA55 (Medicenna Therapeutics), VAL-083 (Dianhydrogalactitol; DelMar Pharmaceuticals), ITI-1000 (pp65 DC Vaccine; Immunomic Therapeutics), Everolimus (Novartis), Ad-RTS-hIL-12 in combination with Veledimex (Ziopharm) and INO-5401 + INO-9012 + Cemiplimab (REGN2810; Inovio Pharmaceuticals), and several others. Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @ 4. Brain Cancer Market Overview at a Glance 5. Brain Cancer Disease Background and Overview 6. Brain Cancer Patient Journey 7. Brain Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan) 8. Brain Cancer Treatment Algorithm, Current Treatment, and Medical Practices 9. Brain Cancer Unmet Needs 10. Key Endpoints of Brain Cancer Treatment 11. Brain Cancer Marketed Therapies 12. Brain Cancer Emerging Drugs and Latest Therapeutic Advances 13. Brain Cancer Seven Major Market Analysis 14. Attribute Analysis 16. Brain Cancer Companies Active in the Market 17. Brain Cancer Access and Reimbursement Overview 18. KOL Views on the Brain Cancer Market 19. Brain Cancer Market Drivers 20. Brain Cancer Market Barriers 21. Appendix 23. Disclaimer *The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents. Request the Sample PDF to Learn More About the Key Offerings of the Report @ About DelveInsight DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Other Trending Healthcare Reports by DelveInsight “Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Recurrent Head And Neck Cancer Squamous Cell Carcinoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma market. Media Contact

MedImmune Frequently Asked Questions (FAQ)

  • When was MedImmune founded?

    MedImmune was founded in 1987.

  • Where is MedImmune's headquarters?

    MedImmune's headquarters is located at One MedImmune Way, Gaithersburg.

  • What is MedImmune's latest funding round?

    MedImmune's latest funding round is Acq - P2P.

  • Who are the investors of MedImmune?

    Investors of MedImmune include AstraZeneca, HBM Healthcare Investments, HBM Partners, BB Biotech Ventures, Bellevue Asset Management and 5 more.

  • Who are MedImmune's competitors?

    Competitors of MedImmune include ISA Pharmaceuticals, CoImmune, Tetraphase Pharmaceuticals, Theraclone Sciences, Akebia Therapeutics and 7 more.

Loading...

Compare MedImmune to Competitors

CoImmune Logo
CoImmune

CoImmune is a company that focuses on the development and manufacture of cell-based therapeutics, operating within the healthcare and biotechnology sectors. The company's main offerings include treatments for unmet medical needs such as cancer, autoimmune, and inflammatory diseases. It was founded in 1997 and is based in Durham, North Carolina. CoImmune operates as a subsidiary of Genexine and SCM Lifescience.

M
MIDA

MIDA, LLC is a research and development drug therapeutic company focused on infectious disease indications.

B
Bexion Pharmaceuticals

Bexion Pharmaceuticals is a company focused on the development of treatments in the fields of Oncology and Central Nervous System (CNS) disorders. The company's main product is a novel S1P modulator, which is designed to provide life-changing treatments for cancer and CNS conditions. Bexion primarily serves the healthcare and pharmaceutical industries. It is based in Covington, Kentucky.

I
ISA Pharmaceuticals

ISA Pharmaceuticals is a company focused on the development of immunotherapeutics in the healthcare and biotechnology industry. The company's main offerings include the creation of synthetic immunotherapeutics designed to harness and direct the body's own defenses to fight against cancer and persistent viral infections. ISA Pharmaceuticals primarily serves the healthcare industry. It was founded in 2004 and is based in Oegstgeest, Netherlands.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and well-being in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

A
Astellas Research Institute of America

Astellas Research Institute of America is focused on cardiology, dermatology, immunology, infectious disease and urology.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.